Business
RepliCel Life Sciences Successfully Closes Financing
RepliCel Life Sciences Successfully Closes Financing.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Life Sciences Successfully Closes Financing\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel Life Sciences Successfully Closes Financing\nCanada NewsWire\nVANCOUVER, Oct. 19, 2017\n\n\n\nShareholders commit to non-brokered private placement in clear support of the Company's partnership strategy\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nVANCOUVER, Oct. 19, 2017 /CNW/ - RepliCel Life Sciences Inc. (\"RepliCel\" or the \"Company\") (OTCQB: REPCD) (TSX.V: RP) (Frankfurt: P6P2), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that, further to its News Releases of October 10, 2017 and October 12, 2017, it has closed its non-brokered private placement of 2,815,881 common shares (each, a \"Share\") at a price of $0.41 per Share for gross proceeds of $1,154,511.21 (the \"Offering\"). The size of the financing was increased to meet demand, structured to include a common share at a standard discount to market price without any accompanying warrants, and was closed within days of the financing being announced.\n\n\n \n \n\n \n\"We are pleased to have secured the support of several key shareholders in the closing of a financing on terms which are favourable to the Company as we execute on the third and final major deliverable we had set out for the Company in 2017,\" stated RepliCel CEO Lee Buckler. \"This sets the stage for us to keep pressing forward while we negotiate partnership agreements anticipated to capitalize the Company through its next stage of development.\"\n\nThe proceeds of the Offering will be used for general working capital and funding ongoing programs including device development as the Company finalizes key partnership agreements currently in negotiation.\n\nIn a statement referencing his January forecast, Buckler continued, \"This year we aimed to deliver successful clinical data, fully functioning device prototypes, and partnership deals. Having delivered on the firs...